Discovery of an antibody for pan-ebolavirus therapy

Wakako Furuyama, Andrea Marzi, Asuka Nanbo, Elaine Haddock, Junki Maruyama, Hiroko Miyamoto, Manabu Igarashi, Reiko Yoshida, Osamu Noyori, Heinz Feldmann, Ayato Takada

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients. However, due to the antigenic differences among the five ebolavirus species, the current therapeutic monoclonal antibodies are only effective against viruses of the species Zaire ebolavirus. Although this particular species has indeed caused the majority of human infections in Central and, recently, West Africa, other ebolavirus species (e.g., Sudan ebolavirus and Bundibugyo ebolavirus) have also repeatedly caused outbreaks in Central Africa and thus should not be neglected in the development of countermeasures against ebolaviruses. Here we report the generation of an ebolavirus glycoprotein-specific monoclonal antibody that effectively inhibits cellular entry of representative isolates of all known ebolavirus species in vitro and show its protective efficacy in mouse models of ebolavirus infections. This novel neutralizing monoclonal antibody targets a highly conserved internal fusion loop in the glycoprotein molecule and prevents membrane fusion of the viral envelope with cellular membranes. The discovery of this highly cross-neutralizing antibody provides a promising option for broad-acting ebolavirus antibody therapy and will accelerate the design of improved vaccines that can selectively elicit cross-neutralizing antibodies against multiple species of ebolaviruses.

Original languageEnglish (US)
Article number20514
JournalScientific Reports
Volume6
DOIs
StatePublished - Feb 10 2016
Externally publishedYes

Fingerprint

Ebolavirus
Antibodies
Neutralizing Antibodies
Monoclonal Antibodies
Therapeutics
Western Africa
Disease Outbreaks
Glycoproteins
Ebola Hemorrhagic Fever
Central Africa
Democratic Republic of the Congo
Virus Internalization
Sudan
Infection

ASJC Scopus subject areas

  • General

Cite this

Furuyama, W., Marzi, A., Nanbo, A., Haddock, E., Maruyama, J., Miyamoto, H., ... Takada, A. (2016). Discovery of an antibody for pan-ebolavirus therapy. Scientific Reports, 6, [20514]. https://doi.org/10.1038/srep20514

Discovery of an antibody for pan-ebolavirus therapy. / Furuyama, Wakako; Marzi, Andrea; Nanbo, Asuka; Haddock, Elaine; Maruyama, Junki; Miyamoto, Hiroko; Igarashi, Manabu; Yoshida, Reiko; Noyori, Osamu; Feldmann, Heinz; Takada, Ayato.

In: Scientific Reports, Vol. 6, 20514, 10.02.2016.

Research output: Contribution to journalArticle

Furuyama, W, Marzi, A, Nanbo, A, Haddock, E, Maruyama, J, Miyamoto, H, Igarashi, M, Yoshida, R, Noyori, O, Feldmann, H & Takada, A 2016, 'Discovery of an antibody for pan-ebolavirus therapy', Scientific Reports, vol. 6, 20514. https://doi.org/10.1038/srep20514
Furuyama W, Marzi A, Nanbo A, Haddock E, Maruyama J, Miyamoto H et al. Discovery of an antibody for pan-ebolavirus therapy. Scientific Reports. 2016 Feb 10;6. 20514. https://doi.org/10.1038/srep20514
Furuyama, Wakako ; Marzi, Andrea ; Nanbo, Asuka ; Haddock, Elaine ; Maruyama, Junki ; Miyamoto, Hiroko ; Igarashi, Manabu ; Yoshida, Reiko ; Noyori, Osamu ; Feldmann, Heinz ; Takada, Ayato. / Discovery of an antibody for pan-ebolavirus therapy. In: Scientific Reports. 2016 ; Vol. 6.
@article{bed6500f6e6a4269afc0727be5be1087,
title = "Discovery of an antibody for pan-ebolavirus therapy",
abstract = "During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients. However, due to the antigenic differences among the five ebolavirus species, the current therapeutic monoclonal antibodies are only effective against viruses of the species Zaire ebolavirus. Although this particular species has indeed caused the majority of human infections in Central and, recently, West Africa, other ebolavirus species (e.g., Sudan ebolavirus and Bundibugyo ebolavirus) have also repeatedly caused outbreaks in Central Africa and thus should not be neglected in the development of countermeasures against ebolaviruses. Here we report the generation of an ebolavirus glycoprotein-specific monoclonal antibody that effectively inhibits cellular entry of representative isolates of all known ebolavirus species in vitro and show its protective efficacy in mouse models of ebolavirus infections. This novel neutralizing monoclonal antibody targets a highly conserved internal fusion loop in the glycoprotein molecule and prevents membrane fusion of the viral envelope with cellular membranes. The discovery of this highly cross-neutralizing antibody provides a promising option for broad-acting ebolavirus antibody therapy and will accelerate the design of improved vaccines that can selectively elicit cross-neutralizing antibodies against multiple species of ebolaviruses.",
author = "Wakako Furuyama and Andrea Marzi and Asuka Nanbo and Elaine Haddock and Junki Maruyama and Hiroko Miyamoto and Manabu Igarashi and Reiko Yoshida and Osamu Noyori and Heinz Feldmann and Ayato Takada",
year = "2016",
month = "2",
day = "10",
doi = "10.1038/srep20514",
language = "English (US)",
volume = "6",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Discovery of an antibody for pan-ebolavirus therapy

AU - Furuyama, Wakako

AU - Marzi, Andrea

AU - Nanbo, Asuka

AU - Haddock, Elaine

AU - Maruyama, Junki

AU - Miyamoto, Hiroko

AU - Igarashi, Manabu

AU - Yoshida, Reiko

AU - Noyori, Osamu

AU - Feldmann, Heinz

AU - Takada, Ayato

PY - 2016/2/10

Y1 - 2016/2/10

N2 - During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients. However, due to the antigenic differences among the five ebolavirus species, the current therapeutic monoclonal antibodies are only effective against viruses of the species Zaire ebolavirus. Although this particular species has indeed caused the majority of human infections in Central and, recently, West Africa, other ebolavirus species (e.g., Sudan ebolavirus and Bundibugyo ebolavirus) have also repeatedly caused outbreaks in Central Africa and thus should not be neglected in the development of countermeasures against ebolaviruses. Here we report the generation of an ebolavirus glycoprotein-specific monoclonal antibody that effectively inhibits cellular entry of representative isolates of all known ebolavirus species in vitro and show its protective efficacy in mouse models of ebolavirus infections. This novel neutralizing monoclonal antibody targets a highly conserved internal fusion loop in the glycoprotein molecule and prevents membrane fusion of the viral envelope with cellular membranes. The discovery of this highly cross-neutralizing antibody provides a promising option for broad-acting ebolavirus antibody therapy and will accelerate the design of improved vaccines that can selectively elicit cross-neutralizing antibodies against multiple species of ebolaviruses.

AB - During the latest outbreak of Ebola virus disease in West Africa, monoclonal antibody therapy (e.g., ZMapp) was utilized to treat patients. However, due to the antigenic differences among the five ebolavirus species, the current therapeutic monoclonal antibodies are only effective against viruses of the species Zaire ebolavirus. Although this particular species has indeed caused the majority of human infections in Central and, recently, West Africa, other ebolavirus species (e.g., Sudan ebolavirus and Bundibugyo ebolavirus) have also repeatedly caused outbreaks in Central Africa and thus should not be neglected in the development of countermeasures against ebolaviruses. Here we report the generation of an ebolavirus glycoprotein-specific monoclonal antibody that effectively inhibits cellular entry of representative isolates of all known ebolavirus species in vitro and show its protective efficacy in mouse models of ebolavirus infections. This novel neutralizing monoclonal antibody targets a highly conserved internal fusion loop in the glycoprotein molecule and prevents membrane fusion of the viral envelope with cellular membranes. The discovery of this highly cross-neutralizing antibody provides a promising option for broad-acting ebolavirus antibody therapy and will accelerate the design of improved vaccines that can selectively elicit cross-neutralizing antibodies against multiple species of ebolaviruses.

UR - http://www.scopus.com/inward/record.url?scp=84958078190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958078190&partnerID=8YFLogxK

U2 - 10.1038/srep20514

DO - 10.1038/srep20514

M3 - Article

VL - 6

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

M1 - 20514

ER -